Cleveland Clinic and partners address treatment, funding, research challenges
Cleveland Clinic, University Hospitals Case Medical Center and Case Western Reserve University are partners in the Case Comprehensive Cancer Center (CCCC), which integrates cancer treatment, research, clinical trials, prevention, screening and education activities in Northern Ohio. This collaborative pools the expertise and resources of its three member institutions and leverages those to acquire research funding and provide advanced cancer care. It is one of 41 National Cancer Institute-designated comprehensive cancer centers nationwide, and one of only a handful of “matrix” centers composed of multiple, independent partners.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“We honestly believe that the sum of the parts greatly exceeds one plus one plus one,” says Brian Bolwell, MD, Chairman of Cleveland Clinic’s Taussig Cancer Institute and CCCC Associate Director.
From Science to Cancer Cures Panel Video
In this video, Dr. Bolwell and fellow CCCC leaders participate in a recent panel discussion organized by the City Club of Cleveland: “From Science to Cancer Cures: How the Case Comprehensive Cancer Center Makes the City of Cleveland Better.” Topics include cancer research projects underway at CCCC; the state of cancer research funding; population-based research and disparities in cancer incidence and treatment access in Northern Ohio; genetic/genomic screening and predictors of cancer risk; integrative oncology; the importance of translational research, and potential solutions for the escalating cost of cancer care.
Photo credit: ©The City Club of Cleveland
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients